Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has successfully produced and genetically screened a new batch of spider silk silkworm eggs, ready for shipment to Vietnam to resume commercial production. Operations were halted in March due to COVID-19, during which the company enhanced its Dragon Silk strain's performance and genetics. CEO Kim Thompson praised the team's progress, emphasizing that these silkworm eggs signify the future of spider silk production.